Post‐
FDA
Approval Experience With Momelotinib in
JAK
Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Perip
American Journal of Hematology | January 8, 2026 | Volume: 101 | Issue: 3 | Pages: 570-576
10.1002/ajh.70203
| PMID 41504170